Recruiting
Phase 3

Thoracic Epidural Analgesia & Four-Quadrant TAP Block

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT03214510

Conditions

Liver and Intrahepatic Bile Duct Disorder

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Bupivacaine

Fentanyl

Hydromorphone Hydrochloride

Implanted Medical Device

Implanted Medical Device

Study Details

Brief summary:

This phase III trial studies how well thoracic epidural analgesia or four-quadrant transversus abdominus plane block works in reducing pain in patients undergoing liver surgery. It is not yet known whether thoracic epidural analgesia or four-quadrant transversus abdominus plane block may help people to recover more completely and more quickly after surgery.

Conditions

Liver and Intrahepatic Bile Duct Disorder

Study ID

NCT03214510

Start date

Oct 4, 2017

Status verified date

Nov, 2026

Completion date

Jul 31, 2027

Anticipated

Primary completion date

Jul 31, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patients undergoing open liver resection without bowel resection/anastomosis for malignancy at MD Anderson Cancer Center
  • Patients must sign a study-specific consent form
  • Platelets >= 100,000/ml (within 30 days of surgery)
  • International normalized ratio (INR) =< 1.5 (within 30 days of surgery)
  • Activated partial thromboplastin time (aPTT) =< 40 (within 30 days of surgery)
  • Patients must have no fever or evidence of infection or other coexisting medical condition that would preclude epidural placement

Exclusion Criteria:

  • Evidence of severe uncontrolled systemic disease or other comorbidity that precludes liver surgery
  • History of chronic narcotic use, defined as 30 days or more of preoperative daily narcotic use, measured from the date of surgery
  • Anaphylaxis to local anesthetics or narcotics
  • Previous or current neurologic disease affecting the lower hemithorax or below
  • Major open abdominal/thoracic surgery in the previous 30 days under general anesthesia
  • Technical contraindications to epidural placement: previous thoracic spinal surgery or local skin or soft tissue infection at proposed site for epidural insertion
  • Use of therapeutic anticoagulation within 5 days of surgery (not including venous thromboembolism prophylaxis)
  • Known bleeding diathesis or coagulopathy
  • Psychiatric (untreated or poorly controlled schizophrenia, major depression, or bipolar disorder), or communication (language) barrier that would preclude accurate assessment of postoperative pain and/or ability to answer questionnaires (need to be able to read, comprehend, and answer questions)
  • Inability to comply with study and/or follow-up procedures
  • Patient refusal to participate in randomization
  • Pregnant women are excluded from this study; women of childbearing potential (defined as those who have not undergone defined as those who have not undergone a hysterectomy or who have not been postmenopausal for at least 12 consecutive months) must agree to practice adequate contraception and to refrain from breast-feeding, as specified in the informed consent
  • Patients with obvious unresectable disease prior to signing informed consent
  • Patients with previous ventral hernia repair, cosmetic abdominoplasty or anterior abdominal wall reconstruction

Study Design

Enrollment

108 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

experimental: Arm I (TAE)

Patients undergo placement of thoracic epidural catheter before surgery. Patients receive hydromorphone hydrochloride and bupivacaine via thoracic epidural catheter every 10 minutes or 3 hours as needed. Patients may receive fentanyl and bupivacaine or plain bupivacaine via thoracic epidural catheter.

experimental: Arm II (TAP)

Patients undergo placement of ultrasound-guided, four-quadrant transversus abdominus plane block. Patients receive plain bupivacaine and liposomal bupivacaine via TAP block.

Interventions

Bupivacaine

Given via thoracic epidural catheter or TAP block

Fentanyl

Given via thoracic epidural catheter

Hydromorphone Hydrochloride

Given via thoracic epidural catheter

Implanted Medical Device

Undergo placement of thoracic epidural catheter

Implanted Medical Device

Undergo placement of ultrasound-guided, four-quadrant transversus abdominus plane block

Liposomal Bupivacaine

Given via TAP block

Questionnaire

Ancillary studies

Primary outcome measure

  • Total length of inpatient stay [ Time Frame: Up to 5 years ]

Central Contacts and Locations

Locations

M D Anderson Cancer Center

Recruiting

Houston, Texas, United States, 77030

Contacts

Principal Investigator:

Timothy E. Newhook

More Information

Sponsor

M.D. Anderson Cancer Center

Last update posted

Nov 17, 2026

Last verified

Nov, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-18. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2026-11-17. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.